Structural vaccinology to thwart antigenic variation in microbial pathogens

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 25, 2011, Pages 10029-10030

  Schneewind, Olaf ^a   Missiakas, Dominique ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS VACCINE;

BACTERIAL GENE; BACTERIUM ISOLATE; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GROUP B STREPTOCOCCAL INFECTION; IMMUNE RESPONSE; NONHUMAN; NOTE; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; VERTICAL TRANSMISSION;

ANIMALS; ANTIGENIC VARIATION; BACTERIA; HUMANS; VACCINES; VIRUSES;

EID: 79959979579     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107324108     Document Type: Note

References (20)

1. Hirst GK, Lancefield RC (1939) Antigenic properties of the type-specific substance derived from group A hemolytic streptococci. J Exp Med 69:425-445.
2. Lancefield RC (1962) Current knowledge of typespecific M antigens of group A streptococci. J Immunol 89:307-313.
3. Nuccitelli A, et al. (2011) Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci USA 108:10278-10283.
4. Tettelin H, et al. (2005) Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome." Proc Natl Acad Sci USA 102:13950-13955.
5. Lauer P, et al. (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309:105. (Pubitemid 40934983)
6. Phares CR, et al. (2008) Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 299:2056-2065. (Pubitemid 351656587)
7. Schrag SJ, et al. (2002) A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 347:233-239. (Pubitemid 34787629)
8. Edwards MS (2008) Group B streptococcal conjugate vaccine: A timely concept for which the time has come. Hum Vaccin 4:444-448.
9. Lancefield RC, Freimer EH (1966) Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 64:191-203.
10. Baker CJ, Kasper DL (1976) Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 294:753-756.
11. Williams C, Masterton R (2008) Pneumococcal immunisation in the 21st century. J Infect 56:13-19.
12. Pannaraj PS, et al. (2008) Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine 26:502-508.
13. Stålhammar-Carlemalm M, Stenberg L, Lindahl G (1993) Protein rib: A novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 177:1593-1603. (Pubitemid 23146126)
14. Santi I, et al. (2009) BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis 200:564-570.
15. Margarit I, et al. (2009) Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm. J Infect Dis 199:108-115.
16. Hendrickx AP, Budzik JM, Oh SY, Schneewind O (2011) Architects at the bacterial surface - sortases and the assembly of pili with isopeptide bonds. Nat Rev Microbiol 9:166-176.
17. Kang HJ, Coulibaly F, Clow F, Proft T, Baker EN (2007) Stabilizing isopeptide bonds revealed in gram-positive bacterial pilus structure. Science 318:1625-1628. (Pubitemid 350233661)
18. Krishnan V, et al. (2007) An IgG-like domain in the minor pilin GBS52 of Streptococcus agalactiae mediates lung epithelial cell adhesion. Structure 15:893-903. (Pubitemid 47212752)
19. Bronze MS, Dale JB (2010) Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections. Am J Med Sci 340:218-225.
20. Dagenais TR, et al. (2009) T-cell responses to the trypanosome variant surface glycoprotein are not limited to hypervariable subregions. Infect Immun 77:141-151.